MARKET

HZNP

HZNP

Horizon Therapeutics Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

90.26
-3.01
-3.23%
After Hours: 90.00 -0.26 -0.29% 19:55 04/19 EDT
OPEN
93.11
PREV CLOSE
93.27
HIGH
93.96
LOW
90.09
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
96.54
52 WEEK LOW
32.54
MARKET CAP
20.22B
P/E (TTM)
55.30
1D
5D
1M
3M
1Y
5Y
Kirr Marbach & Co Llc Buys Horizon Therapeutics PLC, APi Group Corp, The Brink's Co, Sells ...
GuruFocus News · 7h ago
H2 Receptor Blocker Market Size, Market Share, Application, Analysis, Regional Outlook, Growth, Trends and Forecasts 2021 - 2028 By Ameco Research
pune, India, Mon, 19 Apr 2021 00:46:58 / Comserve Inc. / -- The global H2 Receptor Blocker market is segmented by company, region (country), by Type, and by...
Comserve · 22h ago
Horizon Therapeutics' Tepezza shows improvement in thyroid eye disease symptoms
New pooled data from Horizon Therapeutics' (HZNP) Tepezza (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are published in The Lancet Diabetes & Endocrinology.The data further reinforce that Tepezza significantly
Seekingalpha · 3d ago
New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.
Business Wire · 3d ago
New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Business Wire · 3d ago
Horizon Therapeutics' Uplinza shows sustained reduction in NMOSD over 4 years
Horizon Therapeutics (HZNP) announces new long-term data from N-MOmentum trial evaluating Uplinza (inebilizumab-cdon) in patients with Neuromyelitis Optica Spectrum Disorder ((NMOSD)).87.7% of patients who originally received Uplinza in the randomized cont...
Seekingalpha · 3d ago
Global Gastrointestinal Stromal Tumor (GIST) Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Gastrointestinal Stromal Tumor (GIST) Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 4d ago
Gastrointestinal Stromal Tumor (GIST) Drug Market Size, Share, Trend, Volume, Key Players, Production, Import, Export, Application, By Segments, and Types, Company Analysis 2021-2025
Apr 14, 2021 (The Expresswire) -- Global "Gastrointestinal Stromal Tumor (GIST) Drug Market" analysis report provides a detail study of market size of...
The Express Wire · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HZNP. Analyze the recent business situations of Horizon Therapeutics Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HZNP stock price target is 114.00 with a high estimate of 125.00 and a low estimate of 88.00.
EPS
Institutional Holdings
Institutions: 606
Institutional Holdings: 224.64M
% Owned: 100.25%
Shares Outstanding: 224.07M
TypeInstitutionsShares
Increased
172
22.35M
New
124
10.17M
Decreased
161
24.51M
Sold Out
61
4.88M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.31%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/President/Chief Executive Officer/Director
Timothy Walbert
Chief Financial Officer/Executive Vice President
Paul Hoelscher
Chief Human Resource Officer/Executive Vice President
Irina Konstantinovsky
Executive Vice President/Chief Administrative Officer
Barry Moze
Executive Vice President/General Counsel
Brian Beeler
Executive Vice President
Daniel Camardo
Executive Vice President
Geoffrey Curtis
Executive Vice President
Michael DesJardin
Executive Vice President
Vikram Karnani
Executive Vice President
Jeffrey Kent
Executive Vice President
Andy Pasternak
Executive Vice President
Jeffrey Sherman
Executive Vice President
Elizabeth Thompson
Lead Director/Independent Director
Michael Grey
Independent Director
William Daniel
Independent Director
Jeffrey Himawan
Independent Director
Susan Mahony
Independent Director
Gino Santini
Independent Director
James Shannon
Independent Director
H. Thomas Watkins
Independent Director
Pascale Witz
No Data
  • All
  • Financials
  • Insiders
More
About HZNP
Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Webull offers kinds of Horizon Therapeutics PLC stock information, including NASDAQ:HZNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HZNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HZNP stock methods without spending real money on the virtual paper trading platform.